Cystic fibrosis infections: Treatment strategies and prospects

FEMS Microbiology Letters

Volumn 300, Issue 2, 2009, Pages 153-164

  George, Anthony M ^a   Jones, Peter M ^a   Middleton, Peter G ^b  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antibiotic resistance; Burkholderia cepacia; Chemotherapeutic options; Cystic fibrosis infections; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMILORIDE; AMLODIPINE; AZITHROMYCIN; BENZAMIL; BETA LACTAM; BISMUTH; CEFTAZIDIME; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN; DORIPENEM; DORNASE ALFA; FARNESOL; GALLIUM; GENTAMICIN; LINEZOLID; MANNITOL; MEROPENEM; NOVOBIOCIN; POLYETHYLENEIMINE; QUINUPRISTIN; SALBUTAMOL; THEOBROMINE; THEOPHYLLINE; TOBRAMYCIN; UNINDEXED DRUG; VERAPAMIL;

ANTIBIOTIC RESISTANCE; BIOFILM; BURKHOLDERIA CEPACIA; BURKHOLDERIA CEPACIA INFECTION; CYSTIC FIBROSIS; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SHORT SURVEY;

ANTI-BACTERIAL AGENTS; BRONCHOPNEUMONIA; BURKHOLDERIA INFECTIONS; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; PSEUDOMONAS INFECTIONS;

BACTERIA (MICROORGANISMS); BURKHOLDERIA; BURKHOLDERIA CEPACIA; NEGIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 70350233621     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/j.1574-6968.2009.01704.x     Document Type: Short Survey

References (117)

1. Aaron SD (2007) Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms. Pediatr Respir Rev 8 : 256 261.
2. Alekshun MN Levy SB (2007) Molecular mechanisms of antibacterial multidrug resistance. Cell 128 : 1037 1050.
3. Aronoff SC Klinger JD (1984) In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis. Antimicrob Agents Ch 25 : 279 280.
4. Asok Kumar K, Mazumdar K, Dutta NK, Karak P, Dastidar SG Ray R (2004) Evaluation of synergism between the aminoglycoside antibiotic streptomycin and the cardiovascular agent amlodipine. Biol Pharm Bull 27 : 1116 1120.
5. Bergstrom CT, Lo M Lipsitch M (2004) Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. P Natl Acad Sci USA 101 : 13285 13290.
6. Borriello G, Richards L, Ehrlich GD Stewart PS (2006) Arginine or nitrate enhances antibiotic susceptibility of Pseudomonas aeruginosa in biofilms. Antimicrob Agents Ch 50 : 382 384.
7. Boucher RC (2002) An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliver Rev 54 : 1359 1371.
8. Brand PLP (2000) Bronchodilators in cystic fibrosis. J Roy Soc Med 93 : 37 39.
9. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW Smith AL (1999) Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179 : 1190 1195.
10. Burns JL, Gibson RL, McNamara S et al 2001) Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 183 : 444 452.
11. Campana S, Taccetti G, Ravenni N, Masi I, Audino S, Sisi B, Repetto T, Doring G de Martino M (2004) Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex, and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center. J Cystic Fibrosis 3 : 159 163.
12. Chan YY, Ong YM Chua KL (2007) Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. Antimicrob Agents Ch 51 : 623 630.
13. Chen Y, Garber E, Zhao Q, Ge Y, Wikler MA, Kaniga K Saiman L (2005) In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Ch 49 : 2510 2511.
14. Chen YH, Peng CF, Lu PL, Tsai JJ Chen TP (2004) In vitro activities of antibiotic combinations against clinical isolates of Pseudomonas aeruginosa. Kaohslung J Med Sci 20 : 261 267.
15. Chin JN, Jones RN, Sader HS, Savage PB Rybak MJ (2008) Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. J Antimicrob Chemoth 61 : 365 370.
16. Chmiel JF Davis PB (2003) State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir Res 4 : 8 19.
17. Cirioni O, Giacometti A, Silvestri C, Vittoria AD, Licci A, Riva A Scalise G (2006) In vitro activities of tritrpticin alone and in combination with other antimicrobials against Pseudomonas aeruginosa. Antimicrob Agents Ch 50 : 3923 3925.
18. Cohn RC Aronoff SC (1989) The effect of sodium on amiloride-tobramycin synergy in Pseudomonas cepacia. J Lab Clin Med 114 : 724 727.
19. Cohn RC, Jacobs M Aronoff SC (1988) In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis. Antimicrob Agents Ch 32 : 395 396.
20. Cohn RC, Rudzienski L Putnam RW (1992) In vitro antimicrobial activity of amiloride analogs against Pseudomonas. Chemotherapy 38 : 232 234.
21. Cohn RC, Rudzienski L Putnam RW (1995) Verapamil-tobramycin synergy in Pseudomonas cepacia but not Pseudomonas aeruginosa in vitro. Chemotherapy 41 : 330 333.
22. Costerton JW, Stewart PS Greenberg EP (1999) Bacterial biofilms: a common cause of persistent infections. Science 284 : 1318 1322.
23. D'Amato RF, Thornsberry C, Baker CN Kirven LA (1975) Effect of calcium and magnesium ions on the susceptibility of Pseudomonas species to tetracycline, gentamicin, polymyxin B, and carbenicillin. Antimicrob Agents Ch 7 : 596 600.
24. Davies J, Spiegelman GB Yim G (2006) The world of subinhibitory antibiotic combinations. Curr Opin Microbiol 9 : 445 453.
25. Dorwart M, Thibodeau P Thomas P (2004) Cystic fibrosis: recent structural insights. J Cystic Fibrosis 3 : 91 94.
26. Drago L, De Vecchi E, Nicola L, Legnani D, Lombardi A Gismondo AR (2005) In vitro synergy and selection of resistance by fluoroquinolones plus amikacin or β-lactams against extended-spectrum β-lactamase-producing Escherichia coli. J Chemotherapy 17 : 46 53.
27. Drenkard E (2003) Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes Infect 5 : 1213 1219.
28. Eckert R, Brady KM, Greenberg EP, Qi F, Yarbrough DK, He J, McHardy I, Anderson MH Shi W (2006) Enhancement of antimicrobial activity against Pseudomonas aeruginosa by coadministration of G10KHc and tobramycin. Antimicrob Agents Ch 50 : 3833 3838.
29. Elphick HE Tan A (2005) Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Db Syst Rev 2 : CD002007.
30. Engelberg-Kulka H, Sat B, Reches M, Amitai S Hazan R (2004) Bacterial programmed cell death systems as targets for antibiotics. Trends Microbiol 12 : 66 71.
31. Foweraker J, Laughton C, Brown D Bilton D (2005) Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemoth 55 : 921 927.
32. Frangolias DD, Mahenthiralingam E, Rae S, Raboud JM, Davidson AG, Wittman R Wilcox PG (1999) Burkholderia cepacia in cystic fibrosis. Am J Resp Crit Care Med 160 : 1572 1577.
33. Fux CA, Costerton JW, Stewart PS Stoodley P (2005) Survival strategies of infectious biofilms. Trends Microbiol 13 : 34 40.
34. Gibson RL, Burns JL Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Resp Crit Care Med 168 : 918 951.
35. Gilligan PH (1991) Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 4 : 35 51.
36. Gillis RJ, White KG, Choi KH, Wagner VE, Schweizer HP Iglewski BH (2005) Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Ch 49 : 3858 3867.
37. Govan JR Deretic V (1996) Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60 : 539 574.
38. Hall-Stoodley L, Costerton JW Stoodley P (2004) Bacterial biofilms, from the natural environment to infectious diseases. Nat Rev Microbiol 2 : 95 108.
39. Hancock REW Speert DP (2000) Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Update 3 : 247 255.
40. Harrison F (2007) Microbial ecology of the cystic fibrosis lung. Microbiology 153 : 917 923.
41. Helander IM, Alakomi H, Latva-Kala K Koski P (1997) Polyethylenimine is an effective permeabilizer of gram-negative bacteria. Microbiology 143 : 3193 3199.
42. Hill D, Rose B, Pajkos A et al 2005) Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol 43 : 5085 5090.
43. Hoffman LR, D'Argentio DA, MacCross MJ, Zhang Z, Jones RA Miller SI (2005) Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436 : 1171 1175.
44. Holden MT, Seth-Smith HM, Crossman LC et al 2009) The genome of Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis patients. J Bacteriol 191 : 261 277.
45. Hurley JC, Miller GH Smith AL (1995) Mechanism of amikacin resistance in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Diagn Micr Infec Dis 22 : 331 336.
46. Jabra-Rizk MA, Meiller TF, James CE Shirtiff ME (2006) Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility. Antimicrob Agents Ch 50 : 1463 1469.
47. Jacqueline C, Navas D, Batard E, Miegeville AF, Le Mabecque V, Kergueris MF, Bugnon D, Potel G Caillon J (2005) In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Ch 49 : 45 51.
48. Jaffe A, Francis J, Rosenthal M Bush A (1998) Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 351 : 420.
49. Kaneko Y, Thoendel M, Olakanmi O, Britigan BE Singh PK (2007) The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J Clin Invest 117 : 877 878.
50. Khalil H, Chen T, Riffon R, Wang R Wang Z (2008) Synergy between polyethylenimine and different families of antibiotic against a resistant clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Ch 52 : 1635 1641.
51. Kleyman TR Cragoe EJ Jr. (1988) Amiloride and its analogs as tools in the study of ion transport. J Membrane Biol 105 : 1 21.
52. Kolter R Greenberg EP (2006) The superficial life of microbes. Nature 441 : 300 302.
53. Kwon DH Lu CD (2006) Polyamines increase antibiotic susceptibility in Pseudomonas aeruginosa. Antimicrob Agents Ch 50 : 1623 1627.
54. Lang BJ, Aaron SD, Ferris W, Hebert PC MacDonald NE (2000) Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Resp Crit Care Med 162 : 2241 2245. (Pubitemid 32051695)
55. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB Boyle MP (2006) Outcomes of adults with cystic fibrosis infected with antibiotic resistant Pseudomonas aeruginosa. Respiration 73 : 27 33.
56. Leviton IM, Fraimow HS, Carrasco N, Dougherty TJ Miller MM (1995) Tobramycin uptake in Escherichia coli membrane vesicles. Antimicrob Agents Ch 39 : 467 475.
57. Li J, Nation RL, Milne RW, Turnidge JD Coulthard K (2005) Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Ag 25 : 11 25.
58. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR Marshall BC (2001) Predictive 5-yr survivorship model of cystic fibrosis. Am J Epidemiol 153 : 345 352.
59. LiPuma JJ, Rathinavelu S, Foster BK, Keoleian JC, Makidon PE, Kalikin LM Baker JR (2009) In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species. Antimicrob Agents Ch 53 : 249 255.
60. Livermore DM (2005) Tigecycline: what is it, and where should it be used? J Antimicrob Chemoth 56 : 611 614.
61. Lomovskaya O Watkins WJ (2001) Efflux pumps: Their role in antibacterial drug discovery. Curr Med Chem 8 : 1699 1711.
62. Lyczak JB, Cannon CL Pier GB (2000) Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2 : 1051 1060.
63. Lyczak JB, Cannon CL Pier GB (2002) Lung infection associated with cystic fibrosis. Clin Microbiol Rev 15 : 194 222.
64. Macia MD, Blanquer D, Togores B, Sauleda J, Perez JL Oliver A (2005) Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Ch 49 : 3382 3386.
65. MacLeod DL, Nelson LE, Shawar RM, Lin BB, Lockwood LG, Dirks JE, Miller GH, Burns JL Garbar RL (2000) Aminoglycoside resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. J Infect Dis 181 : 1180 1184.
66. Mah TF O'Toole GA (2001) Mechanism of biofilm resistance to antimicrobial agents. Trends Microbiol 9 : 34 39.
67. Mahenthiralingam E, Vandamme P, Campbell ME, Henry DA, Grevelle AM, Wong LT, Davidson AG, Wilcox PG, Nakielna B Speert DP (2001) Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 33 : 1469 1475.
68. Mao W, Warren MS, Lee A, Mistry A Lomovskaya O (2001) MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas aeruginosa. Antimicrob Agents Ch 45 : 2001 2007.
69. McAuley DF Elborn JS (2000) Cystic fibrosis: basic science. Pediatr Respir Rev 1 : 93 100.
70. Medeiros AA, O'Brien TF, Wacker WEC Yulug NF (1971) Effect of salt concentration on the apparent in vitro susceptibility of Pseudomonas and other gram-negative bacilli to gentamicin. J Infect Dis 124 : S59 S64.
71. Middleton PG (2007) Editorial overview: clinical utility of synergy testing for multidrug resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis. Paediatr Respir Rev 8 : 262 263.
72. Middleton PG, Kidd TJ Williams B (2005) Combination aerosol therapy to treat Burkholderia cepacia complex. Eur Respir J 26 : 305 308.
73. Molina A, Del Campo R, Maiz L, Morosini MI, Lamas A, Baquero F Canton R (2008) High prevalence in cystic fibrosis patients of multiresistant hospital-acquired methicillin-resistant Staphyloccus aureus ST228-SCCmecI capable of biofilm formation. J Antimicrob Chemoth 62 : 961 967.
74. Moore RA Hancock RE (1986) Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrob Agents Ch 30 : 923 926.
75. Moskowitz SM, Foster JM, Emerson J Burns JL (2004) Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 42 : 1915 1922.
76. Moss RB (1995) Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. Clin Infect Dis 21 : 839 849.
77. Mulet X, Macia MD, Mena A, Juan C, Perez JL Oliver A (2009) Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. Antimicrob Agents Ch 53 : 1552 1560.
78. Nickel JC, Ruseska I, Wright JB Costerton JW (1985) Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrob Agents Ch 27 : 619 624.
79. Oliver A, Canton R, Campo P, Baquero F Blazquez J (2000) High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288 : 1251 1254.
80. Palmer KL, Mashburn LM, Singh PK Whiteley LM (2005) Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology. J Bacteriol 187 : 2267 2277.
81. Paster BJ, Boches SK, Galvin JL, Ericson RE, Lau CN, Levanos VA, Sahasrabudhe A Dewhirst FE (2001) Bacterial diversity in human subgingival plaque. J Bacteriol 183 : 3770 3783.
82. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE Testa RT (1999) In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Ch 43 : 738 744.
83. Piddock LJV (2006) Multidrug resistance efflux pumps - not just for resistance. Nat Rev Microbiol 4 : 629 636.
84. Proesmans M, Vermeulen F De Boeck K (2008) What's new in cystic fibrosis? From treating symptoms to correction of the basic defect. Eur J Pediatr 167 : 839 849.
85. Radchenko MV, Tanaka K, Waditee R, Oshimi S, Matsuzaki Y, Fukuhara M, Kobayashi H, Takabe T Nakamura T (2006) Potassium/proton antiport system of Escherichia coli. J Biol Chem 281 : 19822 19829.
86. Rajyaguru JM Muszynski MJ (1998) Sensitization of Burkholderia cepacia to antibiotics by cationic drugs. J Antimicrob Chemoth 41 : 277 280.
87. Ramagopal M Lands LC (2000) Inhaled tobramycin and bronchial hyperactivity in cystic fibrosis. Pediatr Pulm 29 : 366 370.
88. Ramsey BW (1996) Management of disease in patients with cystic fibrosis. New Engl J Med 335 : 179 188.
89. Ramsey BW, Pepe MS, Quan JM et al 1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic fibrosis inhaled tobramycin study group. New Engl J Med 340 : 23 30.
90. Regelmann WE, Elliott GR, Warwick WJ Clawson CC (1990) Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 141 : 914 921.
91. Russell AD (1982) Modification of the bacterial cell envelop and enhancement of antibiotic susceptibility. The Control of Antibiotic-Resistant Bacteria (Stuart-Harris CH Harris DM, eds), pp. 119 168. Academic Press Inc., New York, NY.
92. Saiman L (2007) Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. Pediatr Respir Rev 8 : 249 255.
93. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ Campbell PW III. (2003) Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 : 1749 1756.
94. Salunkhe P, Smart CH, Morgan JA, Panagea S, Walshaw MJ, Hart CA, Geffers R, Tümmler B Winstanley C (2005) A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance. J Bacteriol 187 : 4908 4920.
95. Schuster M Greenberg EP (2006) A network of networks: quorum-sensing gene regulation in Pseudomonas aeruginosa. Int J Med Microbiol 296 : 73 81.
96. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ Greenberg EP (2000) Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407 : 762 764.
97. Skindersoe ME, Alhede M, Phipps R, Yang L, Jensen PO, Rasmussen TB, Bjarnsholt T, Tolker-Nielsen T, Høiby N Givskov M (2008) Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Ch 52 : 3648 3663.
98. Smith AL, Doershuk C, Goldmann D et al 1999) Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 134 : 413 421.
99. Smith EE, Buckley DG, Wu Z et al 2006) Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. P Natl Acad Sci USA 103 : 8487 8492.
100. Snydman DR, McDermott LA Jacobus NV (2005) Evaluation of in vitro interaction of daptomycin with gentamicin or β-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves. J Chemotherapy 17 : 614 621.
101. Thompson TB, Crider BP Eagon RG (1985) The kinetics of dihydrostreptomycin uptake in Pseudomonas putida membrane vesicles: absence of inhibition by cations. J Antimicrob Chemoth 16 : 157 163.
102. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arsian H Karaman SO (2006) In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Ag 27 : 224 228.
103. Traczewski MM Brown SD (2006) In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Ch 50 : 819 821.
104. Treerat J, Widmer F, Middleton PG, Iredell J George AM (2008) In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia. FEMS Microbiol Lett 285 : 40 50.
105. Vaisman N, Koren G, Goldstein D, Canny GJ, Tan YK, Soldin S Pencharz P (1987) Pharmacokinetics of inhaled salbutamol in patients with cystic fibrosis versus healthy young adults. J Pediatr 111 : 914 917.
106. Vandamme P, Holmes B, Vancanneyt M et al 1997) Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol 47 : 1188 1200.
107. Veloira WG, Domenico P, LiPuma JJ, Davis JM, Gurzenda E Kazzaz JA (2003) In vitro activity and synergy of bismuth thiols and tobramycin against Burkholderia cepacia complex. J Antimicrob Chemoth 52 : 915 919.
108. Venturi V (2006) Regulation of quorum sensing in Pseudomonas. FEMS Microbiol Rev 30 : 274 291.
109. Wang J, Soisson SM, Young K et al 2006) Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441 : 358 361.
110. Wenzel R, Bate G Kirkpatrick P (2005) Tigecycline. Nat Rev Drug Discov 4 : 809 810.
111. Whiteley M, Lee KM Greenberg EP (1999) Identification of genes controlled by quorum sensing in Pseudomonas aeruginosa. P Natl Acad Sci USA 96 : 13904 13909.
112. Willcox MDP, Zhu H, Conibear TCR, Hume EBH, Givskov M, Kjelleberg S Rice SA (2008) Role of quorum sensing by Pseudomonas aeruginosa in microbial keratitis and cystic fibrosis. Microbiology 154 : 2184 2194.
113. Wolter J, Seeney S, Bell S, Bowler S, Masel P McCormack J (2002) Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis: a randomized trial. Thorax 57 : 212 216.
114. Zemelis VM Jackson GG (1973) Activity of aminoglycoside antibiotics against Pseudomonas aeruginosa: specificity and site of calcium and magnesium antagonism. J Infect Dis 127 : 663 669.
115. Zgurskaya H Nikaido H (2000) Multidrug resistance mechanisms: drug efflux across two membranes. Mol Microbiol 37 : 219 225.
116. Zhang L Mah TF (2008) Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. J Bacteriol 190 : 4447 4452.
117. Zhou J, Chen Y, Tabibi S, Alba L, Garber E Saiman L (2007) Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob Agents Ch 51 : 1085 1088.